Repligen Corp

Repligen is a life sciences company that develops and provides advanced bioprocessing technologies and systems used in the manufacture of biologic drugs, including monoclonal antibodies and cell and gene therapies. The company's products play a critical role in the purification stage of biologics manufacturing, helping ensure that drug products meet rigorous safety and efficacy standards. We believe Repligen is a high-quality compounder operating in a structurally attractive market, as the growing complexity and volume of biologic drug development drive sustained demand for increasingly sophisticated manufacturing tools. Despite near-term pressure, we continue to believe Repligen's market-leading portfolio positions the company well for durable long-term growth.

Repligen, a provider of bioprocessing products, detracted most from our relative returns, as enthusiasm for life-sciences tools generally softened during the period. The concerns were driven by a slowdown in purchasing by the National Institutes of Health (NIH), which affected the entire sector. Importantly, Repligen has no exposure to NIH and offered bullish Q1 guidance, so we remain positive about the business. Also, we expect sentiment surrounding life-sciences tools to improve in the second quarter, which should lead to a reversal of the negative momentum.

Repligen is a life sciences company that produces tools and processes used in the development of biologic drugs. The addition of Repligen to our portfolio reflects our belief in its growth potential and the diversification benefits it brings. We see Repligen as a strong player in the health care sector, particularly as demand for biologic drugs continues to rise, positioning the company well for future success.

Repligen is a US listed biomanufacturing equipment supplier whose products are essential for the growing demand for bio-manufactured medicines. The company is well-positioned to benefit from the US government's focus on re-shoring and the adoption of newer production techniques in the pharmaceutical and biotech sectors. As one of the few specialist equipment suppliers in this space, Repligen's solutions align perfectly with these trends, making it a compelling investment opportunity.

Despite these shorter-term headwinds, we believe the resulting volatility can yield opportunities for favorable long-term returns when quality science and care meet societal health needs.